Intrexon and Amneal Form Second Exclusive Channel Collaboration For APIs
Intrexon, a company specializing in synthetic biology, announced a second exclusive channel collaboration (ECC) with Amneal, a generic development and manufacturing company, to streamline and regulate a scalable production process for a target complex API.
Intrexon’s microbial technology platform is of principal interest to Amneal because, unlike more traditional methods, it requires fewer complex steps and side-steps the need to source from animals and plants. Amneal hopes to use this process to find a more efficient and modern method of producing APIs.
The agreement stipulates that Amneal will gain access to all of Intrexon’s technologies for the development of this particular API, and the two companies will split both development costs and any operating profits which come from a successful product.
Gregory Frost, SVP at Intrexon, indicated that “the value of this potential opportunity” made the “profit-sharing structure” a worthwhile endeavor for both companies.
Frost explains, “The expanded partnership leverages the strengths of both organizations to develop and commercialize a high quality product for patients through a more modernized and controlled manufacturing process.”
Intrexon and Amneal first collaborated in March with the companies’ first ECC, which also focused on establishing a cost-effective biological process for API formulation. The results of this first partnership were beneficial for both companies, as Chintu Patel, CEO of Amneal, reports, “The progress achieved under our initial ECC led to this expansion of our combined efforts.”
Intrexon’s most recent press release reported that this was the third collaboration the company has launched this year due to the growing popularity of its technology platform.
Intrexon recently announced an ECC with Histogenics, a collaboration that will focus on cartilage repair therapies. Collaborative efforts stemming from an ECC with Fibrocell have also recently moved the compound GM-HDF-COL7, indicated for treatment for a connective tissue disorder, closer to clinical trial.
Amneal recently expanded its Glasgow operations into a second facility, the former location of Aphena Pharma Solutions, and plans to use the space as a distribution center.